The Pharmacokinetics of ZiprasidoneTANDON, R.British journal of clinical pharmacology. Supplement. 2000, Vol 49, Num 1, issn 0264-3774, 78 p.Serial Issue

Development and Validation of an HPLC Method for Determination of Ziprasidone and Its Impurities in Pharmaceutical Dosage Forms : New methods for Drug Analysis in Biological Samples and Other MatrixesPAVLOVIC, Marija; MALESEVIC, Marija; NIKOLIC, Katarina et al.Journal of AOAC International. 2011, Vol 94, Num 3, pp 713-722, issn 1060-3271, 10 p.Article

Ziprasidona intramuscular (I.M) na prática psiquiátrica = Ziprasidone intramuscular (I.M) in the clinical psychiatric practiceDA COSTA, Delcir Antonio; DE CASTRO E COSTA, Erico.Psiquiatria biológica (Belo Horizonte). 2004, Vol 12, Num 1, pp 11-13, issn 0104-7787, 3 p.Article

Ziprasidone in the Treatment of Affective Disorders : A ReviewROSA, Adriane R; FRANCO, Carolina; TORRENT, Carla et al.CNS neuroscience & therapeutics (Print). 2008, Vol 14, Num 4, pp 278-286, issn 1755-5930, 9 p.Article

Efficacy of atypical antipsychotics in mood disordersYATHAM, Lakshmi N.Journal of clinical psychopharmacology. 2003, Vol 23, Num 3, pp S9-S14, issn 0271-0749, SUP1Conference Paper

Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of ¹⁴C- and ³H-labeled ziprasidonePRAKASH, C; KAMEL, A; ANDERSON, W et al.Drug metabolism and disposition. 1997, Vol 25, Num 2, pp 206-218, issn 0090-9556Article

Ziprasidone in the management of schizophrenia: The QT interval issue in contextTAYLOR, David.CNS drugs. 2003, Vol 17, Num 6, pp 423-430, issn 1172-7047, 8 p.Article

Safety of antipsychotic drugs: focus on therapeutic and adverse effectsWERNER, Felix-Martin; COVENAS, Rafael.Expert opinion on drug safety. 2014, Vol 13, Num 8, pp 1031-1042, issn 1474-0338, 12 p.Article

Pharmacogenetics of adverse events in schizophrenia treatment: Comparison study of ziprasidone, olanzapine and perazineTYBURA, Piotr; TRZESNIOWSKA-DRUKALA, Beata; BIENKOWSKI, Przemyslaw et al.Psychiatry research (Print). 2014, Vol 219, Num 2, pp 261-267, issn 0165-1781, 7 p.Article

Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE StudyRAMSEY, Timothy L; QIAN LIU; MASSEY, Bill W et al.Schizophrenia research. 2013, Vol 149, Num 1-3, pp 21-25, issn 0920-9964, 5 p.Article

PHOTOSTABILITY STUDY AND IDENTIFICATION OF PHOTODEGRADATION PRODUCTS OF ZIPRASIDONE BY UHPLC-DAD/ESI-Q-TOFSKIBINSKI, Robert.Journal of liquid chromatography & related technologies. 2012, Vol 35, Num 13-16, pp 2097-2112, issn 1082-6076, 16 p.Article

Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-LabeL studyCHEN, Yuejin; BOBO, William V; WATTS, Kara et al.Journal of psychopharmacology (Oxford). 2012, Vol 26, Num 9, pp 1201-1210, issn 0269-8811, 10 p.Article

Two 6-Week, Randomized, Double-Blind, Placebo-Controlled Studies of Ziprasidone in Outpatients With Bipolar I Depression: Did Baseline Characteristics Impact Trial Outcome?LOMBARDO, Ilise; SACHS, Gary; KOLLURI, Sheela et al.Journal of clinical psychopharmacology. 2012, Vol 32, Num 4, pp 470-478, issn 0271-0749, 9 p.Article

Hyperosmolar Hyperglycemic State Associated With Ziprasidone Treatment A Case ReportLETOURNEAU, Genevieve; ABDEL-BAKI, Amal; DUBREUCQ, Simon et al.Journal of clinical psychopharmacology. 2011, Vol 31, Num 5, pp 671-673, issn 0271-0749, 3 p.Article

Metabolic parameters in patients treated with olanzapine or other atypical antipsychoticsOSUNTOKUN, Olawale; MILLEN, Brian; XU, Wen I et al.Journal of psychopharmacology (Oxford). 2011, Vol 25, Num 5, pp 630-638, issn 0269-8811, 9 p.Article

Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective DisorderMICELI, Jeffrey J; TENSFELDT, Thomas G; SHIOVITZ, Thomas et al.Pharmacotherapy. 2010, Vol 30, Num 2, pp 127-135, issn 0277-0008, 9 p.Article

Pharmacotherapy of Bipolar Disorder in Children and Adolescents: Recent ProgressPFEIFER, Jonathan C; KOWATCH, Robert A; DELBELLO, Melissa P et al.CNS drugs. 2010, Vol 24, Num 7, pp 575-593, issn 1172-7047, 19 p.Article

Ziprasidone Treatment of Refractory Generalized Anxiety Disorder: A Placebo-Controlled, Double-Blind StudyLOHOFF, Falk W; ETEMAD, Bijan; MANDOS, Laura A et al.Journal of clinical psychopharmacology. 2010, Vol 30, Num 2, pp 185-189, issn 0271-0749, 5 p.Article

Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorderCITROME, Leslie; REIST, Christopher; PALMER, Liisa et al.Schizophrenia research. 2009, Vol 108, Num 1-3, pp 238-244, issn 0920-9964, 7 p.Article

Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trialZINK, M; KUWILSKY, A; KRUMM, B et al.Journal of psychopharmacology (Oxford). 2009, Vol 23, Num 3, pp 305-314, issn 0269-8811, 10 p.Article

The Role of Antipsychotics in the Management of Behavioural Symptoms in Children and Adolescents with AutismMALONE, Richard P; WAHEED, Ayesha.Drugs (Basel). 2009, Vol 69, Num 5, pp 535-548, issn 0012-6667, 14 p.Article

Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disordersAGID, Ofer; KAPUR, Shitij; WARRINGTON, Lewis et al.Schizophrenia research. 2008, Vol 102, Num 1-3, pp 241-248, issn 0920-9964, 8 p.Article

Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with ZiprasidoneWEIDEN, Peter J; NEWCOMER, John W; LOEBEL, Antony D et al.Neuropsychopharmacology (New York, NY). 2008, Vol 33, Num 5, pp 985-994, issn 0893-133X, 10 p.Article

Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detectionGUODONG ZHANG; TERRY, Alvin V; BARTLETT, Michael G et al.Journal of chromatography. B. 2007, Vol 856, Num 1-2, pp 20-28, issn 1570-0232, 9 p.Article

Acute effects of atypical antipsychotics on whole-body insulin resistance in rats : Implications for adverse metabolic effectsHOUSEKNECHT, Karen L; ROBERTSON, Alan S; ZAVADOSKI, William et al.Neuropsychopharmacology (New York, NY). 2007, Vol 32, Num 2, pp 289-297, issn 0893-133X, 9 p.Article